Anticorps Recombinant de lapin anti-ZFP64

ZFP64 Recombinant Antibody for WB, ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain

Applications

WB, ELISA

Conjugaison

Non conjugué

CloneNo.

240847F9

N° de cat : 83825-3-PBS

Synonymes

ZNF338, Zinc finger protein 64, Zfp-64, Zfp 64, 240847F9

---

Galerie de données de validation

• 

  WB analysis using 83825-3-RR (same clone as 83825-3-PBS)

  Various lysates were subjected to SDS PAGE followed by western blot with 83825-3-RR (ZFP64 antibody) at dilution of 1:10000 incubated at room temperature for 1.5 hours. This data was developed using the same antibody clone with 83825-3-PBS in a different storage buffer formulation.

• 

  Affinity and Kinetic Characterization of 83825-3-RR

  Biolayer interferometry (BLl) kinetic assays of 83825-3-RR against Human ZFP64 were performed. The affinity constant is 1.53 nM.

---

Informations sur le produit

83825-3-PBS cible ZFP64 dans les applications de WB, ELISA et montre une réactivité avec des échantillons Humain

• Réactivité: Humain
• Hôte / Isotype: Lapin / IgG
• Clonalité: Recombinant
• Type: Anticorps
• Immunogène: ZFP64 Protéine recombinante Ag10971
• Nom complet: zinc finger protein 64 homolog (mouse)
• Masse moléculaire calculée: 681 aa, 75 kDa
• Poids moléculaire observé: 70 kDa
• Numéro d’acquisition GenBank: BC041622
• Symbole du gène: ZFP64
• Identification du gène (NCBI): 55734
• Conjugaison: Non conjugué
• Forme: Liquide
• Méthode de purification: Protein A purfication
• Tampon de stockage: PBS only
• Conditions de stockage: Store at -80°C. 20ul contiennent 0,1% de BSA.

Informations générales

ZFP64 (also known as ZNF338) is a member of the Krüppel C2H2-type zinc finger family. ZFP64 is a coactivator of Notch1, mediating mesenchymal cell differentiation. ZFP64 expression was up-regulated in mouse peritoneal macrophages in response to stimulation with the TLR4 ligand LPS with a 2-fold increase. The MLL gene encoding the MLL fusion protein is easily activated by ZFP64. ZFP64 is essential for the continuous production of MLL fusion proteins in blood cancer and produces more cancer cells. Since ZFP64 deletion completely and specifically inhibits MLL fusion protein production and leukemia cascade growth, it is an ideal drug target.

{{ptg:RelatedPrimaryAntibodies}}